Literature DB >> 30498263

Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease.

Jennifer Hind1, Elisabeth Macdonald1, David Lockington2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30498263      PMCID： PMC6461886          DOI： 10.1038/s41433-018-0289-7

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  7 in total

1.  Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.

Authors:  Andrea Leonardi; Gysbert Van Setten; Mourad Amrane; Dahlia Ismail; Jean-Sebastien Garrigue; Francisco C Figueiredo; Christophe Baudouin
Journal:  Eur J Ophthalmol       Date:  2016-04-07       Impact factor: 2.597

Review 2.  TFOS DEWS II Management and Therapy Report.

Authors:  Lyndon Jones; Laura E Downie; Donald Korb; Jose M Benitez-Del-Castillo; Reza Dana; Sophie X Deng; Pham N Dong; Gerd Geerling; Richard Yudi Hida; Yang Liu; Kyoung Yul Seo; Joseph Tauber; Tais H Wakamatsu; Jianjiang Xu; James S Wolffsohn; Jennifer P Craig
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

3.  Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.

Authors:  John D Sheppard; Eric D Donnenfeld; Edward J Holland; Charles B Slonim; Renée Solomon; Kerry D Solomon; Marguerite B McDonald; Henry D Perry; Stephen S Lane; Stephen C Pflugfelder; Sandeep S Samudre
Journal:  Eye Contact Lens       Date:  2014-09       Impact factor: 2.018

4.  Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

Authors:  Frederic Lallemand; Philippe Daull; Simon Benita; Ronald Buggage; Jean-Sebastien Garrigue
Journal:  J Drug Deliv       Date:  2012-02-27

5.  One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.

Authors:  Christophe Baudouin; Maite Sainz de la Maza; Mourad Amrane; Jean-Sébastien Garrigue; Dahlia Ismail; Francisco C Figueiredo; Andrea Leonardi
Journal:  Eur J Ophthalmol       Date:  2017-11-08       Impact factor: 2.597

6.  A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.

Authors:  Christophe Baudouin; Francisco C Figueiredo; Elisabeth M Messmer; Dahlia Ismail; Mourad Amrane; Jean-Sébastien Garrigue; Stefano Bonini; Andrea Leonardi
Journal:  Eur J Ophthalmol       Date:  2017-03-21       Impact factor: 2.597

7.  Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.

Authors:  Andrea Leonardi; Elisabeth M Messmer; Marc Labetoulle; Mourad Amrane; Jean-Sébastien Garrigue; Dahlia Ismail; Maite Sainz-de-la-Maza; Francisco C Figueiredo; Christophe Baudouin
Journal:  Br J Ophthalmol       Date:  2018-03-15       Impact factor: 4.638
  7 in total
  1 in total

1.  Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment.

Authors:  Gerd Geerling; Samer Hamada; Stefan Trocmé; Sten Ræder; Xiangjun Chen; Claudia Fassari; Ines Lanzl
Journal:  Ophthalmol Ther       Date:  2022-03-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.